The chief executive officer of Debiopharm's corporate subsidiary will be replaced by Marc Cikes in early June

Tanja Dowe has announced her departure from Debiopharm Innovation Fund, the corporate fund of the Switzerland-based biopharmaceuticals corporation, Debiopharm.

Tanja Dowe
Tanja Dowe

After serving more than five years as the fund’s chief executive officer, Dowe will be replaced by Marc Cikes who will take over the role on June 1st. 

“I will be moving on to pursue new steps in my career,” says Dowe, “It has been…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?